PBYI News and Press, Puma Biotechnology Inc

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of alisertib for the treatment of patients with advanced osimertinib-resistant epidermal growth factor receptor-mutated (EGFR-mutated) non-small cell lung cancer (NCT04085315) at the 2024 American Soc...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of biomarker findings from a Phase II randomized clinical trial of alisertib alone vs. alisertib + fulvestrant for the treatment of patients with endocrine and CDK4/6 inhibitor (CDK 4/6i) resistant, h...

2024-05-28 09:07:41 ET More on Puma Biotechnology Puma Biotechnology: A Story In Flux Heading Into Mid-2024 Puma Biotech pares gain amid Wyeth victory in Tagrisso patent case against AstraZeneca Puma Biotechnology Non-GAAP EPS of -$0.05 beats by $0.10, revenue of $43...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, is set to join the broad-market Russell 3000 ® Index at the conclusion of Russell Investments’ annual reconstitution of its comprehensive set of U.S. and global equity indexes on June 28 and effective after U.S....

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the release of abstracts on alisertib to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The ASCO Annual Meeting will be held at McCormick Place in Chicago and online from May 31-...

2024-05-17 15:10:02 ET More on Puma Biotechnology Puma Biotechnology: A Story In Flux Heading Into Mid-2024 Puma Biotechnology, Inc. (PBYI) Q1 2024 Earnings Call Transcript Puma Biotechnology, Inc. 2024 Q1 - Results - Earnings Call Presentation Puma Biotechno...

2024-05-05 04:02:32 ET Summary Puma Biotechnology's pipeline is evolving, but analysts express "Hold" sentiments due to its stagnant pipeline over the past few years. The company's lone approved product, neratinib, is being marketed for HER2-positive breast cancer, but competition...

2024-05-02 22:11:10 ET Puma Biotechnology, Inc. (PBYI) Q1 2024 Earnings Conference Call May 02, 2024 4:30 PM ET Company Participants Mariann Ohanesian – Senior Director-Investor Relations Alan Auerbach – Chief Executive Officer, President and Chairman o...

2024-05-02 16:34:32 ET More on Puma Biotechnology Puma Biotechnology, Inc. 2023 Q4 - Results - Earnings Call Presentation Puma Biotechnology, Inc. (PBYI) Q4 2023 Earnings Call Transcript Puma Biotechnology Q1 2024 Earnings Preview Puma Biotech cleared to tria...

2024-05-01 17:35:51 ET More on Puma Biotechnology Puma Biotechnology, Inc. 2023 Q4 - Results - Earnings Call Presentation Puma Biotechnology, Inc. (PBYI) Q4 2023 Earnings Call Transcript Puma Biotech cleared to trial Takeda-partnered breast cancer therapy in U.S. ...